moclobemide

Summary

Summary: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.

Top Publications

  1. Kennedy S, Eisfeld B, Dickens S, Bacchiochi J, Bagby R. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000;61:276-81 pubmed
    ..of this report is to evaluate disturbances in sexual drive/desire and arousal/orgasm in 107 patients who met criteria for major depressive disorder and received treatment with either moclobemide, paroxetine, sertraline, or venlafaxine.
  2. Stein D, Cameron A, Amrein R, Montgomery S. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol. 2002;17:161-70 pubmed
    ..A randomized placebo-controlled, double-blind multi-site trial of moclobemide, a reversible inhibitor of monoamine oxidase A, was undertaken with 390 subjects...
  3. Warwick J, Carey P, van der Linden G, Prinsloo C, Niehaus D, Seedat S, et al. A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder. Metab Brain Dis. 2006;21:241-52 pubmed
    ..specific reuptake inhibitor (SSRI) citalopram and the reversible mono-amine oxidase-A inhibitor (RIMA) moclobemide have both been used successfully for the treatment of social anxiety disorder (SAD)...
  4. Schneier F, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz M. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry. 1998;172:70-7 pubmed
    b>Moclobemide, a reversible inhibitor of monoamine oxidase A, previously has been reported to have efficacy in the treatment of social phobia.
  5. Jouvent R, Le Houezec J, Payan C, Mikkelsen H, Fermanian J, Millet V, et al. Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation. Psychiatry Res. 1998;79:267-75 pubmed
    The onset of action (during the first 2 weeks of treatment) of moclobemide (450 mg/day), a reversible MAO-A inhibitor, was compared in a double-blind, multi-center trial with clomipramine (150 mg/day) on dimensional and global depressive ..
  6. Atmaca M, Kuloglu M, Tezcan E, Unal A. Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002;17:401-5 pubmed
    ..In the present study, the efficacy and side-effect profile of citalopram, an SSRI, and moclobemide, the only MAOI used in Turkey, were compared...
  7. Søgaard J, Lane R, Latimer P, Behnke K, Christiansen P, Nielsen B, et al. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol. 1999;13:406-14 pubmed
    ..Diagnostic Scale (ADDS) score=4] were randomized to 12 weeks of double-blind treatment with sertraline or moclobemide in a multicentre, parallel-group clinical trial...
  8. Laska A, von Arbin M, Kahan T, Hellblom A, Murray V. Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study. Cerebrovasc Dis. 2005;19:125-32 pubmed
    ..Some data suggest that antidepressant drugs could be beneficial also for functional improvement. This prompted us to investigate whether regression from aphasia after acute stroke could be enhanced by antidepressive drug therapy...
  9. Muller D, Schulze T, Macciardi F, Ohlraun S, Gross M, Scherk H, et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. Pharmacopsychiatry. 2002;35:157-8 pubmed

More Information

Publications85

  1. Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand. 2001;104:104-9 pubmed
    To determine the relative efficacy, tolerability and risk of precipitating mania of moclobemide and imipramine in the treatment of bipolar depression.
  2. Vanderkooy J, Kennedy S, Bagby R. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry. 2002;47:174-80 pubmed
    ..There is no commonly accepted standard for comparing antidepressant-induced side effects. This study evaluates a clinician-administered scale, the Toronto Side Effect Scale (TSES), in a natural practice clinic...
  3. Cho J, Yu K, Jang I, Yang B, Shin S, Yim D. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53:393-7 pubmed
    The pharmacokinetics of omeprazole and its metabolites in healthy subjects were evaluated to determine if a single dose of moclobemide inhibited CYP2C19 activity.
  4. Papakostas G, Fava M. A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can J Psychiatry. 2006;51:783-90 pubmed
    To compare response rates among patients with major depressive disorder (MDD) treated with either moclobemide, an antidepressant thought to simultaneously enhance both noradrenergic and serotonergic neurotransmission, or selective ..
  5. Uhlenhuth E, Warner T, Matuzas W. Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. J Clin Psychopharmacol. 2002;22:275-84 pubmed
    ..This report presents similar analyses of data from a study using moclobemide. Patients (N = 452) with panic disorder were randomized to placebo or a fixed dose of moclobemide (75, 150, 300,..
  6. Prasko J, Dockery C, Horacek J, Houbová P, Kosova J, Klaschka J, et al. Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuro Endocrinol Lett. 2006;27:473-81 pubmed
    ..b>moclobemide and supportive guidance, B. group cognitive-behavioral therapy and pill placebo, and C...
  7. Chambost M, Liron L, Peillon D, Combe C. [Serotonin syndrome during fluoxetine poisoning in a patient taking moclobemide]. Can J Anaesth. 2000;47:246-50 pubmed
    ..To present a case of delayed serotonin syndome (SS), a less well-known adverse effect of fluoxetine intoxication...
  8. Schreiber S, Getslev V, Weizman A, Pick C. The antinociceptive effect of moclobemide in mice is mediated by noradrenergic pathways. Neurosci Lett. 1998;253:183-6 pubmed
    b>Moclobemide is an antidepressant which affects the monoaminergic neurotransmitter system through a reversible inhibition of monoamine oxidase (MAO), preferentially type A...
  9. Alpsoy E, Ozcan E, Cetin L, Ozgur O, Er H, Yilmaz E, et al. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study. J Am Acad Dermatol. 1998;38:197-200 pubmed
    ..Psychosocial factors have been implicated in the onset and exacerbation of psoriasis...
  10. Onder E, Tural U, Aker T. A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake. Eur Psychiatry. 2006;21:174-9 pubmed
    ..study, the patients who met DSM-IV criteria for PTSD were randomly assigned to flexible doses of fluoxetine, moclobemide, or tianeptine...
  11. Chiou S, Ku H, Tsai T, Lin H, Chen L, Chien C, et al. Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. Br J Pharmacol. 2006;148:587-98 pubmed
    1. Moclobemide (MB) is an antidepressant drug that selectively and reversibly inhibits monoamine oxidase-A...
  12. Philipp M, Tiller J, Baier D, Kohnen R. Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups. Eur Neuropsychopharmacol. 2000;10:305-14 pubmed
    To compare the emergent sexual effects of moclobemide and selective serotonin reuptake inhibitors (SSRIs) during acute and maintenance therapy in routine practice.
  13. Dimpfel W. Rat electropharmacograms of the flavonoids rutin and quercetin in comparison to those of moclobemide and clinically used reference drugs suggest antidepressive and/or neuroprotective action. Phytomedicine. 2009;16:287-94 pubmed publisher
    ..The pattern of changes approached that obtained after 2.5mg/kg of moclobemide during the first hour as revealed by discriminant analysis in comparison to a large matrix of other drugs with ..
  14. Pini S, Amador X, Dell osso L, Baldini Rossi N, Cassano P, Savino M, et al. Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide. Int Clin Psychopharmacol. 2003;18:15-21 pubmed
    To compare the efficacy and tolerability of moclobemide versus paroxetine for the treatment of depression with comorbid anxiety disorders...
  15. Yu K, Yim D, Cho J, Park S, Park J, Lee K, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001;69:266-73 pubmed
    b>Moclobemide, an antidepressant with selective monoamine oxidase-A inhibitory action, is known to be metabolized by CYP2C19 and is also reported to be an inhibitor of CYP2C19, CYP2D6, and CYP1A2...
  16. Verleye M, Steinschneider R, Bernard F, Gillardin J. Moclobemide attenuates anoxia and glutamate-induced neuronal damage in vitro independently of interaction with glutamate receptor subtypes. Brain Res. 2007;1138:30-8 pubmed
    ..The present study examined the in vitro effects of the antidepressant and type-A monoamine oxidase inhibitor, moclobemide, in neuronal-astroglial cultures from rat cerebral cortex exposed to anoxia (for 5 and 7 h) or to glutamate (2 ..
  17. Li Y, Zhang Y, Liu Y, Wang H, Yuan L, Luo Z. Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice. Acta Pharmacol Sin. 2004;25:1408-12 pubmed
    ..To explore the action mechanism of antidepressants...
  18. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003;9:97-140 pubmed
    b>Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied in anxiety disorders...
  19. Cryan J, Page M, Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl). 2005;182:335-44 pubmed
    ..However, few studies have compared the effects of short- and long-term antidepressant treatment on behaviors in the test, despite the need to treat patients chronically to produce clinical effects...
  20. de Mello M, Myczcowisk L, Menezes P. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. J Psychother Pract Res. 2001;10:117-23 pubmed
    ..compared the outcomes of 35 outpatients with dysthymic disorder randomized to receive either treatment with moclobemide and interpersonal therapy (IPT) or moclobemide and routine clinical management...
  21. Bonnet U, Leniger T, Wiemann M. Moclobemide reduces intracellular pH and neuronal activity of CA3 neurones in guinea-pig hippocampal slices-implication for its neuroprotective properties. Neuropharmacology. 2000;39:2067-74 pubmed
    Mechanisms underlying the neuroprotective properties of the weak MAO-A inhibitor moclobemide are not understood...
  22. Downes M, Whyte I, Isbister G. QTc abnormalities in deliberate self-poisoning with moclobemide. Intern Med J. 2005;35:388-91 pubmed
    ..Several medications have been found to prolong the QT interval in overdose. This can predispose to torsade de pointes-type ventricular tachycardia...
  23. Smith D, Fisher D, Blier P, Ilivitsky V, Knott V. The separate and combined effects of monoamine oxidase A inhibition and nicotine on the mismatch negativity event related potential. Pharmacol Biochem Behav. 2015;137:44-52 pubmed publisher
    ..non-smoking males, we investigated the separate and combined effects of nicotine and MAO-A inhibition via moclobemide (75mg) on the optimal-5 variation of the MMN paradigm...
  24. Nowakowska E, Chodera A, Kus K, Nowak P, Szkilnik R. Reversal of stress-induced memory changes by moclobemide: the role of neurotransmitters. Pol J Pharmacol. 2001;53:227-33 pubmed
    ..In this study, we investigated the effects of chronic stress procedure and moclobemide in rats, and the influence of chronic stress on the levels of monoamines: noradrenaline (NE), dopamine (DA) and ..
  25. Baker G, Sowa B, Todd K. Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?. J Psychiatry Neurosci. 2007;32:313-5 pubmed
  26. Covey L, Sullivan M, Johnston J, Glassman A, Robinson M, Adams D. Advances in non-nicotine pharmacotherapy for smoking cessation. Drugs. 2000;59:17-31 pubmed
    ..Encouraging results have also been observed for nortriptyline and moclobemide. Studies of combined treatments using non-nicotine medications (amfebutamone, mecamylamine, oral dextrose) with ..
  27. Curtin F, Berney P, Kaufmann C. Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms. J Psychopharmacol. 2002;16:271-2 pubmed
    A case of moclobemide discontinuation syndrome who predominantly presented with influenza-like symptoms is presented...
  28. Jastrzebska Wiesek M, Siwek A, Partyka A, Kołaczkowski M, Walczak M, Smolik M, et al. Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. Naunyn Schmiedebergs Arch Pharmacol. 2018;391:37-49 pubmed publisher
    ..p.) coadministration of EMD386088 (2.5 mg/kg) and imipramine (15 mg/kg), reboxetine (5 mg/kg), moclobemide (10 mg/kg), or bupropion (10 mg/kg) evoked significant antidepressant-like activity, whereas no effect was ..
  29. Schneier F. Treatment of social phobia with antidepressants. J Clin Psychiatry. 2001;62 Suppl 1:43-8; discussion 49 pubmed
    ..The SSRIs are well tolerated and consistently have been shown to be efficacious in controlled trials. ..
  30. Liu F, Zhu N, Qiu L, Wang J, Wang W. [Application of R-based multiple seasonal ARIMA model, in predicting the incidence of hand, foot and mouth disease in Shaanxi province]. Zhonghua Liu Xing Bing Xue Za Zhi. 2016;37:1117-20 pubmed publisher
    ..Multiple seasonal ARIMA (2,1,0)×(1,1,0)12 model could be used to successfully predict the incidence of hand, foot and mouth disease in Shaanxi province. ..
  31. Lestra C, D Amato T, Ghaemmaghami C, Perret Liaudet A, Broyer M, Renaud B, et al. Biological parameters in major depression: effects of paroxetine, viloxazine, moclobemide, and electroconvulsive therapy. Relation to early clinical outcome. Biol Psychiatry. 1998;44:274-80 pubmed
    ..biopterins were measured in 27 depressed patients before and during four different ATs (paroxetine, viloxazine, moclobemide, or electroconvulsive therapy)...
  32. Rybakowski J. Moclobemide in pregnancy. Pharmacopsychiatry. 2001;34:82-3 pubmed
    We report on the case of female patient with chronic dysthymia, who took moclobemide at 300 mg/day throughout her first pregnancy. The course of pregnancy was healthy, and natural delivery was uneventful...
  33. Chebili S, Abaoub A, Mezouane B, Le Goff J. [Antidepressants and sexual stimulation: the correlation]. Encephale. 1998;24:180-4 pubmed
    ..A precise study concludes that moclobemide improve significantly all components of sexual function...
  34. Stein M. Medication treatments for panic disorder and social phobia. Depress Anxiety. 1998;7:134-8 pubmed
    ..First, two social phobia studies which used the monoamine oxidase type A inhibitors brofaromine and moclobemide are considered...
  35. Tatarczyńska E, Kłodzińska A, Stachowicz K, Chojnacka Wójcik E. Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test. Eur J Pharmacol. 2004;487:133-42 pubmed
    ..imipramine, the selective noradrenaline reuptake inhibitor desipramine or the monoamine oxidase-A inhibitor moclobemide, administered in combination with the 5-HT(1A) receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]..
  36. Khan S, Abbas G, Ahmed F, Rahman A, Dar A. Effect of dichloromethane fraction of Areca catechu nut on monoamines associated behaviors and tyramine pressor sensitivity in rodents. Pak J Pharm Sci. 2014;27:303-7 pubmed
    ..These results suggest that the dichloromethane fraction of A. catechu nut primarily elevates serotonin levels (probably via monoamine oxidase A inhibition) and does not induce cheese effect. ..
  37. Eli R, Fasciano J. A chronopharmacological preventive treatment for sleep-related migraine headaches and chronic morning headaches: Nitric oxide supersensitivity can cause sleep-related headaches in a subset of patients. Med Hypotheses. 2006;66:461-5 pubmed
    ..It consists of melatonin and moclobemide taken during the night, close the end of the sleep cycle so as to achieve the maximum concentrations...
  38. Skibiński R, Komsta Ł. Application of curve resolution algorithms in the study of drug photodegradation kinetics -- the example of moclobemide. J AOAC Int. 2012;95:708-12 pubmed
    The photodegradation of moclobemide was studied in methanolic media...
  39. Contreras Mora H, Rowland M, Yohn S, Correa M, Salamone J. Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions. Pharmacol Biochem Behav. 2018;166:13-20 pubmed publisher
    ..5mg/kg) being effective. In contrast, neither the MAO-A selective antagonist moclobemide nor the nonselective drug pargyline reversed the effects of tetrabenazine, and moclobemide decreased lever ..
  40. Vuori E, Henry J, Ojanpera I, Nieminen R, Savolainen T, Wahlsten P, et al. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction. 2003;98:365-8 pubmed
    Four deaths following the ingestion of moclobemide and MDMA ('ecstasy') are described. The probable cause of death in each case was serotonin syndrome as a result of an interaction between the two drugs...
  41. Chen X, Zheng S, Le J, Qian Z, Zhang R, Hong Z, et al. Ultrasound-assisted low-density solvent dispersive liquid-liquid microextraction for the simultaneous determination of 12 new antidepressants and 2 antipsychotics in whole blood by gas chromatography-mass spectrometry. J Pharm Biomed Anal. 2017;142:19-27 pubmed publisher
    ..determination of 12 new antidepressants (norfluoxetine, fluoxetine, fluvoxamine, agomelatine, mirtazapine, moclobemide, melitracen, N-desmethylmirtazapine, maprotiline, sertraline, citalopram, paroxetine) and 2 antipsychotics (..
  42. Rogde S, Hilberg T, Teige B. Fatal combined intoxication with new antidepressants. Human cases and an experimental study of postmortem moclobemide redistribution. Forensic Sci Int. 1999;100:109-16 pubmed
    Three cases are presented in which death was caused by suicidal intoxication with moclobemide in combination with a selective serotonin reuptake inhibitor...
  43. Ginovart N, Meyer J, Boovariwala A, Hussey D, Rabiner E, Houle S, et al. Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab. 2006;26:330-44 pubmed
    ..studies were performed in healthy volunteers at placebo conditions and after treatment with clinical doses of moclobemide. In either condition, a two-tissue compartment model (2CM) provided better fits to the data than a one-tissue ..
  44. Girard P, Verniers D, Pansart Y, Gillardin J. Efficacy of moclobemide in a rat model of neurotoxicant-induced edema. Can J Physiol Pharmacol. 2007;85:556-61 pubmed
    The potent antidepressant effect of moclobemide, a selective and reversible type A monoamine oxidase (MAO) inhibitor, is clinically established...
  45. Wesołowska A, Tatarczyńska E, Nikiforuk A, Chojnacka Wójcik E. Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice. Eur J Pharmacol. 2007;555:43-7 pubmed
    ..test in mice, we examined the effect of the following antidepressants: citalopram, imipramine, desipramine and moclobemide (which are characterized by different mechanisms of action), administered in combination with the selective 5-..
  46. van Haelst I, van Klei W, Doodeman H, Kalkman C, Egberts T. Antidepressive treatment with monoamine oxidase inhibitors and the occurrence of intraoperative hemodynamic events: a retrospective observational cohort study. J Clin Psychiatry. 2012;73:1103-9 pubmed
    ..To investigate the occurrence of intraoperative hemodynamic events when antidepressive treatment with monoamine oxidase inhibitors (MAOIs) was continued during anesthesia...
  47. Antal E, Hendershot P, Batts D, Sheu W, Hopkins N, Donaldson K. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol. 2001;41:552-62 pubmed
    The primary objective of this study was to compare the effects of oral linezolid with moclobemide and placebo on the pressor response to oral tyramine...
  48. Hickie I, Wilson A, Wright J, Bennett B, Wakefield D, Lloyd A. A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. J Clin Psychiatry. 2000;61:643-8 pubmed
    ..To date, no medical or psychotropic therapies have provided clear symptomatic benefit...
  49. Bielecka A, Paul Samojedny M, Obuchowicz E. Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture. Naunyn Schmiedebergs Arch Pharmacol. 2010;382:409-17 pubmed publisher
    ..We have investigated for the first time whether the antidepressant, moclobemide (a reversible selective inhibitor of monoamine oxidase-A) has an influence on pro-inflammatory cytokines [..
  50. Bonnet U. Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties. CNS Drug Rev. 2002;8:283-308 pubmed
    The benzamide moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA). It has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively in anxiety disorders...
  51. Misztal G, Skibiński R, Olajossy M, Paw B. LC determination of moclobemide and three metabolites in plasma. J Pharm Biomed Anal. 2002;30:1277-85 pubmed
    b>Moclobemide and three metabolites were quantified using 1 ml of plasma and solid-phase extraction with Bakerbond CN column after the addition of nadolol as the internal standard (I.S.)...
  52. Lapatto Reiniluoto O, Kivistö K, Neuvonen P. Efficacy of activated charcoal versus gastric lavage half an hour after ingestion of moclobemide, temazepam, and verapamil. Eur J Clin Pharmacol. 2000;56:285-8 pubmed
    To compare the efficacy of activated charcoal and gastric lavage in preventing the absorption of moclobemide, temazepam, and verapamil 30 min after drug ingestion.
  53. Henkel V, Mergl R, Allgaier A, Kohnen R, Moller H, Hegerl U. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res. 2006;141:89-101 pubmed
    ..The available data are insufficient for a direct comparison between MAOIs and selective serotonin reuptake inhibitors...
  54. Plenis A, Oledzka I, Baczek T. Classification of LC columns based on the QSRR method and selectivity toward moclobemide and its metabolites. J Pharm Biomed Anal. 2013;78-79:161-9 pubmed publisher
    ..The assay was carried out for the LC separation of moclobemide and its metabolites in human plasma, using a set of 24 stationary phases...
  55. Yu L, Yao T, Zeng S. In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan. Chem Biol Interact. 2003;146:263-72 pubmed
    ..Cimetidine and moclobemide produced no significant effect on the metabolism of zolmitriptan...
  56. Villarinho J, Pinheiro K, Pinheiro F, Oliveira S, Machado P, Martins M, et al. The antinociceptive effect of reversible monoamine oxidase-A inhibitors in a mouse neuropathic pain model. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:136-42 pubmed publisher
    ..is understudied, we evaluated the potential antinociceptive effect of the reversible MAO-A inhibitors moclobemide and 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in a mouse neuropathic pain model induced by ..
  57. Calabrese J, Rapport D, Kimmel S, Shelton M. Controlled trials in bipolar I depression: focus on switch rates and efficacy. Eur Neuropsychopharmacol. 1999;9 Suppl 4:S109-12 pubmed
    ..The low switching rates observed in these studies of lamotrigine, paroxetine and moclobemide may indicate a special application of these drugs in the management of patients prone to antidepressant-induced ..
  58. Kruger M, Dahl A. The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci. 1999;249 Suppl 1:S19-24 pubmed
    The primary objectives of this multicenter study were to determine the efficacy and safety of moclobemide, a selective reversible inhibitor of monoamino oxidase A, as drug treatment in DSM-III-R panic disorder with and without ..
  59. Carruba M, Cuzzolaro M, Riva L, Bosello O, Liberti S, Castra R, et al. Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial. Int Clin Psychopharmacol. 2001;16:27-32 pubmed
    A 6-week double-blind placebo-controlled trial was carried out to examine the efficacy and tolerability of moclobemide, a monoamine oxidase type A selective and reversible inhibitor, in the treatment of bulimia nervosa...
  60. Camaris C, Little D. A fatality due to moclobemide. J Forensic Sci. 1997;42:954-5 pubmed
    A fatality due to ingestion of the antidepressant drug moclobemide is reported. Moclobemide is a selective and reversible inhibitor of monoamine oxidase type A...
  61. Beaumont G, Gringras M, Hobbs F, Drury V, Freeling P, Tylee A, et al. A randomized, double-blind, multi-centre, parallel-group study comparing the tolerability and efficacy of moclobemide and dothiepin hydrochloride in depressed patients in general practice. Int Clin Psychopharmacol. 1993;7:159-65 pubmed
    ..double-blind, multi-centre, parallel-group study compared the tolerability and efficacy of 450 mg of moclobemide and 75-150 mg of dothiepin in the management of depressed patients in general practice...
  62. Cesura A, Kettler R, Imhof R, Da Prada M. Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide. Psychopharmacology (Berl). 1992;106 Suppl:S15-6 pubmed
    The mode of interaction of the reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide with the enzyme was investigated...
  63. Eli R, Fasciano J. A chronopharmacological diagnostic test and treatment for bipolar disorder and depression: nitric oxide release during sleep causes it to become depressogenic in a subset of patients. Med Hypotheses. 2006;66:72-5 pubmed
    ..It consists of melatonin taken at bedtime and the antidepressant moclobemide, taken as close to the onset of stage IV sleep as possible...
  64. Wiśniewski G, Jakitowicz J, Nowicki Z, Pankiewicz P. [Prognostic value of pharmaco-EEG in depression treated with moclobemide]. Psychiatr Pol. 2002;36:93-8 pubmed
    Ten women (age 41.90 +/- 5.67) with depressive episode (moderate, mild; ICD-10) were treated with moclobemide (450 mg)...
  65. Tarim E, Bagis T, Kilicdag E, Erkanli S, Aslan E, Kuscu E. Moclobemide in the treatment of hot flashes in postmenopausal women. Adv Ther. 2002;19:258-65 pubmed
    This randomized, prospective, double-blind study evaluated the efficacy and tolerability of moclobemide, a reversible, selective inhibitor of monoamine oxidase-A, in reducing the frequency and severity of hot flashes...
  66. Kool S, Dekker J, Duijsens I, de Jonghe F, Puite B. Efficacy of combined therapy and pharmacotherapy for depressed patients with or without personality disorders. Harv Rev Psychiatry. 2003;11:133-41 pubmed
    ..provided for three successive steps in case of intolerance or inefficacy: fluoxetine, amitriptyline, and moclobemide. In addition to pharmacotherapy, the combined-therapy condition included 16 sessions of Short Psychodynamic ..
  67. Freezer A, Salem A, Irvine R. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide. Brain Res. 2005;1041:48-55 pubmed
    ..In humans, co-administration of MDMA with the reversible MAO-A inhibitor moclobemide has led to increased apparent toxicity with ensuing fatalities...
  68. Labbate L, Croft H, Oleshansky M. Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. J Clin Psychiatry. 2003;64 Suppl 10:11-9 pubmed
    ..Few proposed treatment options, apart from avoidance, have proved effective for antidepressant-associated sexual dysfunction, which can have negative consequences on depression management...
  69. Li Y, Liu Y, Huang W, Luo Z. Cytoprotective effect is one of common action pathways for antidepressants. Acta Pharmacol Sin. 2003;24:996-1000 pubmed
    ..To explore the possible common action mechanism of antidepressants...
  70. Jimenez Genchi A. Immediate switching from moclobemide to duloxetine may induce serotonin syndrome. J Clin Psychiatry. 2006;67:1821-2 pubmed
  71. Vaiva G, De Lenclave M, Bailly D. Treatment of comorbid opiate addiction and attention-deficit hyperactivity disorder (residual type) with moclobemide: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:609-11 pubmed
    b>Moclobemide is a specific and reversible monoamine oxidase-A (MAO-A) inhibitor. Studies show that it is an effective and well-tolerated treatment for attention-deficit hyperactivity disorder (ADHD)...
  72. Wesołowska A, Nikiforuk A. The selective 5-HT(6) receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats. Eur J Pharmacol. 2008;582:88-93 pubmed publisher
    ..of SB-399885 (3 mg/kg) and imipramine (20 mg/kg), desipramine (20 mg/kg), bupropion (5 mg/kg) or moclobemide (20 mg/kg), produced significant anti-immobility action, whereas SB-399885 (3 mg/kg) given jointly with ..
  73. Rakic A, Miljkovic B, Pokrajac M, Vucicevic K. High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma. J Pharm Biomed Anal. 2007;43:1416-22 pubmed
    ..and simple high-performance liquid chromatographic (HPLC) method was developed for the determination of moclobemide and its two major metabolites, Ro 12-5637 and Ro 12-8095, in human plasma. Sample preparation (0...
  74. Höjer J, Personne M, Skagius A, Hansson O. [Serotonin syndrome. Several cases of this often overlooked diagnosis]. Lakartidningen. 2002;99:2054-5, 2058-60 pubmed
    ..Four of these cases are presented together with a review of the literature. All patients had overdosed moclobemide and in one case this was the only drug taken...
  75. Li Y, Zhang Y, Liu Y, Wang H, Cao J, Guan T, et al. Inhibition of N-methyl-D-aspartate receptor function appears to be one of the common actions for antidepressants. J Psychopharmacol. 2006;20:629-35 pubmed
    ..625-10 microM) or moclobemide (2.5, 10 microM) antagonized NMDA 300 M induced-lesion in PC12 cells...
  76. Getova D, Dimitrova D, Roukounakis I. Effects of the antidepressant drug moclobemide on learning and memory in rats. Methods Find Exp Clin Pharmacol. 2003;25:811-5 pubmed
    b>Moclobemide is a well known drug with antidepressant action. The aim of this study was to investigate the effects of moclobemide on learning and memory processes in Sprague Dawley rats...